EULAR Advocacy: EULAR RheumaMap
The RheumaMap was developed by European Alliance of Associations for Rheumatology (EULAR) under the leadership of Professor Iain McInnes, then the EULAR Treasurer, who led a task force of international experts from the field of rheumatology within Europe to develop the document. Professor McInnes describes it as a key tool for change: “The RheumaMap lays out the need to develop a long-term strategy to effectively reduce the burden of RMDs, which still affect every fourth European citizen, totalling approximately 120 million people. This document, which is testament to the tremendous power of team work, identifies the unmet needs and main challenges in research and innovation in RMDs – and it proposes key areas where long-term strategic efforts can help reduce the enormous burden of these conditions in Europe.”
The Interest Group on Rheumatic and Musculoskeletal Diseases (RMDs), the “ Research Roadmap to transform the lives of people with Rheumatic and Musculoskeletal Diseases ” was launched in the European Parliament in 2017. The RheumaMap, which has been designed as a ‘research roadmap’, was researched and put together by EULAR drawing on the expertise of the European RMD community, from scientific societies to health professional and patient organisations. For many of the over 200 RMDs – where very often there is no cure available – it defines the key issues to tackle through prioritisation of research funding at national and European level.
RheumaMap 2019: Making the case for unmet needs in rheumatology
Rheumatic and musculoskeletal diseases (RMDs) are among the most prevalent, disabling and burdensome, non- communicable diseases in Europe eliciting high costs for European healthcare and social security budgets. The causes of more than 200 RMDs (including a number of rare diseases) are unknown. Although there are still no cures current treatments allow for a significant improvement in clinical manifestations and disability prevention.
To read the 2019 version of the RheumaMap, download the document here
Read about previous versions of the RheumaMap
EULAR Advocacy Newsletter
EULAR is committed to bringing rheumatic and musculoskeletal diseases (RMDs) onto the EU's agenda. Sign up to the EULAR Advocacy newsletter to keep up with the changes that our organisation is working towards in the area of policy and legislation to help achieve better social and economic outcomes for the many millions of people affected by these chronic and debilitating diseases across Europe.
About EULAR Advocacy
EU Advocacy is a key activity for a European umbrella organisation like the European Alliance of Associations for Rheumatology (EULAR).
EULAR Advocacy Partnerships
EULAR is committed to partner with organisations and scientific medical societies at a EU and national level towards improving research funding, social policy legislation and quality of care; assisting advocacy actions on the national and international levels around rheumatic and musculoskeletal diseases (RMDs).
EULAR Policy Statements
As part of its advocacy activities, EULAR produces and adopts a number of documents and declarations that are used to express EULAR’s position and/or demands on different policy issues.
EU Parliament Interest Group on RMDs
The European Parliament Interest Group on Rheumatic and Musculoskeletal Diseases (RMDs) was created in 2009 on the occasion of World Arthritis Day (12 October) and was re-established during the current parliamentary term (2014-2019).
Links to other organisations
Partnerships that help to increase the knowledge of the organisations involved and the impact they can have on the political stage.
EULAR description on Rheumatic and Musculoskeletal Diseases (RMDs)